Pharmaceutical companies pay millions to doctors to promote GLP-1 drugs

GLP-1 medications pharmaceutical marketing weight-loss drugs physician payments Eli Lilly

An analysis of US government data reveals that pharmaceutical companies have paid millions of dollars to physicians to promote GLP-1 weight-loss and diabetes medications. Since 2018, these companies have made payments to more than 250,000 individual doctors and prescribing professionals.

One specific case involves physician Carlos Campos in Central Texas, who received nearly one million dollars over a seven-year period from pharmaceutical firms to advocate for the benefits of these drugs. Major manufacturers Eli Lilly and Novo Nordisk are identified as key players in this marketing strategy, which targets prescribing doctors to drive sales of their revolutionary medications.

Entities

Carlos Campos · Eli Lilly · Novo Nordisk · The Washington Post · United States

Claims

What the coverage asserts, and how many sources carry each claim.

[● 5 SOURCES] Since 2018, pharmaceutical companies have made payments to more than 250,000 individual doctors and prescribing professionals. www.leinetal24.de · www.mannheim24.de
[● 5 SOURCES] Physician Carlos Campos received nearly one million dollars over seven years from pharmaceutical companies to promote GLP-1 drugs. www.leinetal24.de · www.mannheim24.de
[● 5 SOURCES] An analysis of US government data shows pharmaceutical companies have paid millions to doctors to promote GLP-1 medications. www.leinetal24.de · www.mannheim24.de
[● 5 SOURCES] Eli Lilly and Novo Nordisk are the largest manufacturers of weight-loss medications. www.leinetal24.de · www.mannheim24.de